Next Article in Journal
Monitoring of Allograft Adaptation After Kidney Transplantation in Pediatric Patients by Targeted Plasma Metabolomics
Previous Article in Journal
An Integrated Transcriptomic and Proteomic Approach Uncovers the Molecular Mechanisms of Hypoosmotic Adaptation in Scylla paramamosain Megalopa
Previous Article in Special Issue
Exploring the Antimicrobial and Antiviral Properties of Cryptic Peptides from Human Fibrinogen
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Plant Antimicrobial Oligopeptides with Anticancer Properties as a Source of Biologically Active Peptides—An In Silico Study

by
Anna Jakubczyk
1,
Kamila Rybczyńska-Tkaczyk
2,* and
Anna Grenda
3
1
Department of Biochemistry and Food Chemistry, University of Life Sciences in Lublin, 20-950 Lublin, Poland
2
Department of Environmental Microbiology, University of Life Sciences in Lublin, 20-950 Lublin, Poland
3
Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(18), 9189; https://doi.org/10.3390/ijms26189189
Submission received: 5 August 2025 / Revised: 12 September 2025 / Accepted: 16 September 2025 / Published: 20 September 2025
(This article belongs to the Special Issue Antimicrobial and Antiviral Peptides: 2nd Edition)

Abstract

Biologically active peptides can be obtained with various research methods, depending on the starting material, biological activity, and intended use. To use the most efficient method, it is worth combining in silico and in vitro experiments. Among the tools that can support an in silico analysis are databases such as the Antimicrobial Peptide Database (AMPD) or BIOPEP-UWM. The aim of this study was to make an in silico hydrolysis of peptides with anticancer properties selected from the AMP database, using pepsin, trypsin, and chymotrypsin. Most peptides obtained had properties inhibiting ACE and dipeptidyl peptidase IV activity. Among the resulting peptides, those with the sequence AR, CF, ER, TF, IY, ER, AW, GF, TW, SK and IM are potentially resistant to peptidase from microbial action. An analysis of the peptides’ characteristics showed that peptides with the sequence AR, EK, ER and SK are well-soluble in water and have high affinity for protein and ligand binding. Peptides with the sequence TF, IL and PF are unstable. Thermostable peptides are PGL, IL, GL, IY, VF, PL, IM and QL. The results of the study may be used to design in vitro experiments.

1. Introduction

Plant peptides are ubiquitously found in various parts of plants, including roots, seeds, flowers, stems, and leaves [1]. They can be extracted using several methods such as enzymatic hydrolysis, microbial fermentation, and chemical hydrolysis. Enzymatic hydrolysis is particularly favored due to its ability to yield specific products under mild conditions [2]. Biologically active plant peptides are small protein fragments derived from plants that exhibit a wide range of physiological activities. These peptides are produced through enzymatic processes and metabolic pathways in plants and are known for their significant medicinal and therapeutic potential. Plant-derived peptides have been shown to possess various biofunctional properties, including antibacterial, antioxidant, antihypertensive, anti-inflammatory, immunomodulatory, anticancer and antidiabetic ones [1,3,4].
Antibacterial plant-derived peptides (AMPs) are emerging as promising alternatives to conventional antibiotics due to their potent antimicrobial properties and lower likelihood of inducing resistance. Plant-derived AMPs exhibit broad-spectrum antimicrobial activity against various pathogens, including Gram-positive and Gram-negative bacteria, fungi, and viruses [5,6,7]. Combining AMPs with traditional antibiotics can enhance antibacterial efficacy and reduce the emergence of resistance. For instance, the combination of AMPs with erythromycin showed a synergistic effect, improving bacterial killing and reducing resistance development [8]. Moreover, AMPs have a lower propensity for inducing resistance compared to traditional antibiotics. This is partly due to their multiple mechanisms of action, which make it harder for bacteria to develop resistance [5,9]. These peptides are part of the plant’s innate defense system and exhibit broad-spectrum activity against various pathogens, including bacteria, fungi, viruses, and even cancer cells [10,11,12,13]. AMPs are typically small, cationic, and amphipathic molecules, often containing fewer than 100 amino acids. They can be rich in cysteine residues, forming disulfide bonds that contribute to their stability. Common types of AMPs include defensins, thionins, hevein-like peptides, knottins, snakins, lipid transfer proteins, and cyclotides [10,11,12,13,14]. Many AMPs act by permeabilizing bacterial membranes, leading to cell lysis. This can occur through various models, such as toroidal pore, barrel-stave, and carpet mechanisms. Some peptides interfere with bacterial metabolic processes or target specific intracellular components, further inhibiting bacterial growth. Certain AMPs induce reactive oxygen species (ROS) production within bacterial cells, causing oxidative damage and protein leakage [10,15,16,17]. AMPs hold significant promise as alternatives to conventional antibiotics, offering broad-spectrum antimicrobial activity and lower resistance potential. They are applied, for example, in medicine, agriculture and food industries, and the ongoing research aims at overcoming current challenges and enhancing the efficacy of such peptides [11,12,13,15,18]. AMPs are being explored for their potential in treating human infections, including those caused by multidrug-resistant bacteria. They are also being investigated for their anticancer and antiviral properties [11,19,20]. AMPs can enhance plant disease resistance and are used in developing bio-pesticides and transgenic plants to protect crops from pathogens [11,13]. Due to their antimicrobial properties, AMPs are considered for use in food preservation to prevent spoilage and extend shelf life [10,15].
There is a class of plant AMPs that have demonstrated anticancer activity, with some showing the ability to bind to cancer cell membranes and cause lysis. Modern personalized therapies are now available for oncological patients, which extend Progression-Free Survival (PFS) and Overall Survival (OS). In addition to the still widely used chemotherapy, molecularly targeted therapy and immunotherapies are becoming increasingly applicable [21,22].
Chemotherapy often causes serious side effects and leads to treatment resistance. Moreover, when using personalized therapies, there are different types of side effects, especially visible in immunotherapy targeted at immune checkpoints (ICI). Further, despite the effectiveness of modern cancer treatments, some patients experience resistance to therapy, the causes of which are not fully understood [23,24]. Because of this, there is an ongoing search for therapeutic methods that overcome primary or secondary resistance.
New compounds for cancer treatment with high efficacy and low toxicity are being sought. An example of such compounds are AMPs, which exert their anticancer effects primarily by destroying cell membranes; therefore, AMPs also have unique advantages in combating drug-resistant cancer cells [25]. Limitations in clinical use of AMPs, such as low proteolytic and chemical stability or salt sensitivity can be overcome by several methods, including stabilization, hybridization, cyclization, fragmentation, multimerization, alteration of amino acids, and conjugation or ligation [26]. Studies in animal models indicate that their anticancer mechanisms involve direct cytotoxicity, modulation of the host immune response, and direct impact on the tumor microenvironment, resulting in tumor regression, inhibition of metastasis, and improved survival rates [27].
Defensins, thionins, and cyclotides have antibacterial, antifungal, antiviral, and cytotoxic effects, which can be used to fight cancer cells. Peptides such as Pyrularia, Viscotoxin, Ligatoxin, and β-Purothionin have been shown to possess anticancer properties [28]. Cyclotides are known for their structural stability and the ability to interact with cell membranes. Their stability and tolerance to modifications of amino acid residues mean that they can be considered as scaffolds in the design of new anticancer drugs. The research by Flores-Alvarez et al. [29] demonstrates that defensin γ-thionin (Capsicum chinense) exhibits cytotoxic effects on K562 leukemia cells (IC50 = 290 μg/mL; 50.26 μM), while showing no toxicity toward human peripheral blood mononuclear cells. The findings revealed that γ-thionin did not alter the membrane potential, but it affected the mitochondrial membrane potential (∆Ψm) and triggered intracellular calcium release. Furthermore, γ-thionin promoted apoptosis in K562 cells without activating caspases 8 or 9. Notably, calpain activation was observed after one hour of treatment, indicating that γ-thionin induces caspase-independent apoptosis [29]. A number of plant-derived cyclotides have been described as demonstrating anticancer activity against breast, lung, cervical, intestinal or lymphoma cancer cells [30,31,32]. For example, modified Kalata B1 was tested as a vascular endothelial growth factor A (VEGF-A) antagonist [33]. A native cyclotide (MCoTI-II), on the other hand, has been tested for action against the BCR-ABL fusion protein (found as a product of the BCR/ABL gene fusion in leukemias) or the anti-CTLA-4 immune checkpoint, whose blockade with monoclonal antibodies is an immunotherapy registered and successfully used in immunogenic tumors [34,35]. This indicates the potential for using plant-derived peptides, with possible chemical modification, to develop drugs in the area of precision oncology. Moreover, it has been shown that Kalata B1 peptide can penetrate cells through both endocytosis and direct membrane translocation. Both pathways are initiated by targeting phosphatidylethanolamine phospholipids on the cell surface and by inducing changes in the cell membrane. This approach can be used to deliver drugs to cancer cells, which are characterized by a higher proportion of phosphatidylethanolamine phospholipids exposed on their surface [36]. Lunasin, a peptide found in soybean, wheat, and barley, has demonstrated anti-proliferative effects on cancer cells. Studies have found that lunasin inhibits non-small cell lung cancer cell proliferation by acting as an antagonist of αv integrin and a histone acetylation modulatory agent [37]. Lunasin alters the expression of G1-phase-specific components of the cyclin-dependent kinase complex, increases the level of cyclin-dependent kinase inhibitor 1B (p27Kip1), decreases the level of phosphorylated AKT (AKT Serine/Threonine Kinase 1) and, as a result, inhibits the phosphorylation of the retinoblastoma (RB) protein, simultaneously promoting its activation. Therefore, it is indicated that lunasin can inhibit non-small-cell lung cancer (NSCLC) proliferation by suppressing RB phosphorylation and inhibiting the cell cycle of tumor cells [38]. It is also asserted that lunasin is potentially applicable in treatment of metastatic, refractory and recurrent melanoma. It has been suggested that lunasin can reduce melanoma cell pools with stem cell properties. It acts by decreasing the phosphorylation of the activating intracellular kinases Focal Adhesion Kinase (FAK) and AKT, and reduces the acetylation of lysine residues in histones H3 and H4. In addition, it is indicated that lunasin’s ability to affect cancer-initiating cells is partly due to suppression of integrin signaling [39]. Research on the anticancer properties of peptides is now advancing, and is very promising if only in the form of developing supermolecular anticancer drugs that inhibit many of the abilities of cancerous cells [40]. Mechanisms related to self-organization and enzymatic regulation in cancer cells appear to be good targets for peptide-based potential anti-cancer therapies, whose efficacy may arise from reducing the communicative capacity of cancer cells and blocking signaling pathways.
Moreover, peptides can influence the tumor microenvironment, which participates in carcinogenesis at each of its stages. Through the use of appropriately prepared/modified peptides, the response to the applied registered treatment can be modulated, so they can serve as agents in supportive therapies [41]. Of course, the use of peptides in anti-cancer therapies is not without its challenges, including how to deliver them to the body or tumor cells. Therefore, nanotechnologies are being developed for the delivery of peptide molecules that will ensure efficient, precise and safe transport to their site of action [42].
There are many methods for obtaining biologically active peptides. The choice of a method depends on the starting material and the desired effect. Each method has its limitations and advantages. Among the methods for obtaining and characterizing biologically active peptides, there are in silico ones. In order to increase the accuracy and reliability of research on bioactive peptides, in silico studies are combined with in vitro and in vivo studies. This approach is particularly useful for identifying bioactive peptides from food sources and other biological materials. In silico methods are used to design peptides with high specificity and low toxicity for therapeutic purposes [43,44].
The aim of this study was to make an in silico hydrolysis of antimicrobial peptides with anticancer properties. Proteolytic enzymes of the digestive system, i.e., pepsin, trypsin and chymotrypsin, were selected for hydrolysis. The peptides obtained were tested in terms of resistance to the action of enzymes produced by gastrointestinal microorganisms and were analyzed for their physicochemical properties.

2. Results

2.1. Peptide Sequences After In Silico Hydrolysis with Gastrointestinal Track Enzymes

The peptides found in the Antimicrobial Peptide Database (AMPD) were in silico hydrolyzed under gastrointestinal tract conditions, and the all results are shown in Table S1. If any oligopeptide digestion result is not listed in the table, it means that no active fragments were found. The peptides obtained were shown according to their activity (Table 1). The resulting peptides consist of two and three amino acids. Most of the peptides were identified as angiotensin-converting enzyme (ACE) or dipeptidyl peptidase IV inhibitors. This is due to the amino acid composition of the obtained peptides, which determines their biological activity.

2.2. Peptide Sequences After Hydrolysis with Microbial Enzymes

In order to check whether the enzymes obtained are potentially resistant to the action of proteolytic enzymes produced by microorganisms in the small intestine, the peptides were hydrolyzed using oligopeptidase F and proteinase P1. The results are shown in Table 2. More than half of those peptides can be hydrolyzed by enzymes of microbial origin and can constitute a source of free amino acids for the body, especially since exogenous amino acids and proline, which is a conditionally exogenous amino acid, are released in a state of illness or stress. Those that remain intact can enter the bloodstream and be transported to their destination.

2.3. Characterization of the Peptides

The peptides were characterized according to physicochemical properties. Peptides with the sequences AR, EK, ER, PK, SK and QH were characterized by BI higher than 2.48, which suggested their high binding to the cell membrane or other protein receptors. Moreover, the peptides PK, SK, EK and ER are characteristic for a domain rich in basic residue, which promotes DNA/RNA binding. They are often found in nuclear localization sequences (NLS). This peptide signal sequence mediates the transfer of proteins from the cytoplasm into the nucleus. They are related, inter alia, to the action of importin α/β1, involved in the transport of functional proteins across the nuclear membrane. Importins cooperate with types of nuclear localization signals and take part in mechanisms of protein import into the nucleus. Thus, they are also involved in the transport of transcription factors, thereby participating in the regulation of gene expression. They may affect the activation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), whether by participating directly in the regulation of gene expression by retention in the nucleus and by acting with other regulating proteins [45]. PTPN18 (Protein Tyrosine Phosphatase Non-Receptor Type 18) is a suppressor of breast cancer metastasis, thereby providing a potential effective antimetastatic therapeutic strategy. It has been proven that the nuclear (not the cytoplasmic) level is a factor beneficial in preventing metastasis, which is related to the expression and functioning of NLS-responsive importin β2 transporters [46]. Moreover, importins are being considered as new therapeutic targets in cancer [47].
All of the peptides have pI values of around or higher than 6. According to the results, it appears that only three peptides, with the sequence TF, IL or PF, are unstable. Some of the peptides—PGL, IL, GL, IY, VF, PL, IM and QL—are characterized by high thermostability. These peptides can be transported through the PEPT1/PEPT2 system; as short peptides, they can be transported by specific transporters in the small intestine. Most of the peptides obtained have a positive GRAVY index, meaning that they are hydrophobic. They can be components of membrane proteins. However, eight of the peptides are hydrophilic and can be components of soluble proteins. Their sequence is AR, EK, ER, PK, TW, PW, SK and QH. Only seven peptides, with the sequence AR, EK, ER, GK, PK SK and QH, are soluble in water. These peptides occur naturally in organisms and perform signaling, hormonal or neuromodulator functions.

3. Discussion

Biologically active peptides consist of 2 to 30 amino acid residues and can perform various biological and technological functions in the production of food, dietary supplements and drugs. There are many methods for obtaining biologically active peptides, and the choice of a method depends on the efficiency, application and source of these compounds. The most common methods include enzymatic hydrolysis of proteins, isolation of free peptides or de novo synthesis. Due to the fact that proteins are often the reserve material of plants, they are a good source of biologically active peptides. Currently, many experimental methods are preceded by data analysis and the use of in silico methods, enabled by various tools. This provides a basis for further research and is often considered a preliminary study or analysis of the research problem [48,49,50].
Plant-derived peptides obtained from the hydrolysis of plant proteins exhibit a wide range of stimulating activities, e.g., antioxidant, anti-inflammatory and immunomodulatory ones beneficial for human health. These peptides are bioactive compounds with diverse physiological functions, exhibiting a wide range of inhibitory activities against various enzymes, like inhibiting angiotensin-converting enzyme (ACE), renin, dipeptidyl peptidase-IV (DPP-IV) and peptidases, with significant potential for therapeutic applications in managing hypertension, metabolic disorders, neurodegenerative and inflammatory disorders [51,52,53,54].
A very important group of biologically active peptides consists of AMPs, which play a significant role in combating the activity of pathogenic microorganisms by being able to prevent their growth and colonization. They are natural biopolymers in organism protection. They exhibit broad activity against bacteria, viruses, and fungi [55]. Peptides are often multifunctional, which endows them with greater possibilities of use. It is true that their pharmacological use may be difficult due to pharmacokinetic disadvantages such as low proteolytic and chemical stability, high cytotoxicity and hemolytic activity, and salt sensitivity [26,27].
Nevertheless, plant-derived antimicrobial oligopeptides are a good source of peptides that exhibit various biological functions and which can be released in the digestive system. In this study, 57 oligopeptides with anticancer properties were selected from the AMP database and hydrolyzed in silico with gastrointestinal enzymes. AMP databases contain information on oligopeptide sequences with various properties, confirmed by scientific research. Due to the increasing need to identify compounds with anticancer properties, peptides that demonstrate anticancer properties and can also serve as a source of biologically active peptides were selected for this study. These peptides are inactive within the oligopeptide molecule and released under the influence of digestive enzymes. Oligopeptides were hydrolyzed with proteolytic enzymes of the gastrointestinal tract, i.e., pepsin, trypsin, and chymotrypsin, to simulate hydrolysis in the body. To obtain and design new foods or dietary supplements, it is necessary to understand the structure and characteristics of hydrolysis and absorption in an in silico [56] and then in vitro [57] model of the gastrointestinal tract so as to provide a theoretical basis for the action of bioactive compounds in the body. The majority of the di- and tripeptides obtained were those with antioxidant properties, inhibiting ACE activity, and dipeptidyl peptidase (Table 1). In vitro models offer several methods for simulating gastrointestinal conditions. These include pH changes, hydrolysis with single enzymes, sequences of digestive enzymes, and more complex models that incorporate, for example, intestinal peristalsis or gut microbiota. In studies on the absorption of bioactive compounds, experiments on intestinal epithelial cell lines are most commonly used [58]. The in silico methods offer cost-effective, less time-consuming high-throughput alternatives to traditional in vitro and in vivo methods. Many studies confirm the reliability of in silico studies in in vitro research. McFarland et al. (2024) [59] performed in silico and in vitro digestibility analysis of a sweet protein derived from sweet truffle (Mattirolomyces terfezioides). For in silico digestibility, PeptideCutter was employed using the enzyme pepsin at pH 1.3, along with trypsin and chymotrypsin, to predict the protein digestion products. In vitro digestibility was determined using a commercial proteolytic enzyme kit with pepsin, trypsin, and chymotrypsin [59]. In silico digestion of the protein indicated high digestibility (43 peptide fragments were obtained), which was confirmed by experimental studies. In vitro mass spectral analysis confirmed the presence of all predicted tryptic fragments. The correlation between the in silico and in vitro results confirms the validity and reliability of the computational model in predicting the production of peptides that may exhibit biological activity.
Studies on the protein stability of the Serendipity berry plant (Dioscoreophyllum cumminsii (Stapf) Diels) also support the in silico approach. Both in vitro and in silico results indicate >90% digestibility, and the in silico results indicate 15 pepsin cleavage sites and 15 trypsin cleavage sites, resulting in an average fragment size of 3.43 amino acids. Therefore, it can be concluded that the protein tested is highly digestible. The small peptide fragments predicted by the in silico model (averaging approximately 3.5 amino acids) suggest that the protein will most likely be efficiently broken down and available for absorption, which correlates well with the high digestibility observed in the study using proteolytic enzymes [60]. In silico studies do not take into account many factors, such as sample preparation, hydrolysis time, or intestinal peristalsis. However, they allow for preliminary conclusions as to whether a given research material is suitable for research and whether it is worth further characterization. Other studies also confirm comparable in silico and in vitro results. In studies of bean proteins as a functional component, the BIOPEP-UWM database was used to determine in silico protein digestibility, using pepsin, trypsin, and chymotrypsin. In the experimental studies, pepsin, pancreatic juices, amylase, and bile acid were used. The in silico digestion results showed that peptides with lengths of two to five amino acids were released in the largest amount (51.13%), followed by free amino acids (34.09%), and finally, peptides longer than five amino acids were present in the smallest amount (14.77%). In vitro digestibility ranged from 48.2% to 63.6%, depending on the protein content and whether the samples were cooked or uncooked [61].
Elisha et al. studied cow’s and human milk proteins as a potential source of peptides with ACE- and dipeptidyl peptidase IV-inhibiting properties. In this case, in silico studies also confirmed experimental studies using proteolytic enzymes from the digestive system [62].
Therefore, it is advisable to conduct in silico studies, which significantly shortens the time and is less time-consuming and labor-intensive. It also allows for the appropriate selection of research material, which can contribute to increased effectiveness of in vitro and in vivo studies.
Plant-derived peptides have garnered significant attention due to their potent antioxidant properties, which can protect against oxidative damage and related diseases. These peptides are primarily obtained through the enzymatic hydrolysis of plant proteins, which breaks down the proteins into smaller, bioactive fragments [63,64,65,66,67]. Plant-derived antioxidant peptides are sourced from various plants, including cereals, legumes, oilseeds, fruits, and vegetables [52,68]. These peptides exhibit strong antioxidant activities by scavenging free radicals, chelating metal ions, and modulating antioxidant enzymes. They help reduce intracellular reactive oxygen species and enhance the body’s defense mechanisms [66,67,69]. The antioxidant activity is influenced by the peptides’ amino acid composition and sequence. Peptides with hydrophobic amino acids (e.g., L or V) and those containing sulfur-containing (C or M) or aromatic amino acids (F, W or Y) tend to have stronger antioxidant properties [67]. These findings correspond well with the results obtained in our study, where the antioxidant peptides were indicated as TW, IY, AW and PW (Table 1). The antioxidant effects are often linked to the peptides’ability to modulate key oxidative stress pathways, such as Keap1-Nrf2-ARE, MAPK, NF-κB, and PI3K/AKT/mTOR. They also influence the expression of pro- and anti-apoptotic proteins and antioxidant enzymes [66,69].
Plant-derived antihypertensive peptides are gaining attention as natural supplements for managing hypertension owing to their efficacy, safety, and non-toxic side effects. These peptides are fragments of plant proteins that exhibit biological activity, particularly in inhibiting enzymes involved in blood pressure regulation [51,70,71,72]. Many plant-derived peptides inhibit the angiotensin-converting enzyme (ACE), which plays a crucial role in blood pressure regulation by promoting vasodilation through increased nitric oxide production [51,52,71]. Some peptides also inhibit renin, another enzyme involved in the renin-angiotensin system (RAS), which helps control blood pressure. These peptides may also interact with angiotensin II receptors, further contributing to their antihypertensive effects [71]. Some plant-derived peptides enhance the biosynthesis of nitric oxide (NO) in the vascular endothelium. NO is a vasodilator that helps relax blood vessels, thereby reducing blood pressure [71]. Certain plant-derived peptides can modulate the Renin–angiotensin–aldosterone system (RAAS), which plays a crucial role in blood pressure regulation [53].
The relationship between the amino acid composition and ACE inhibition has not been fully elucidated. Dipeptides including L, Q, P, M or A in their structure have been shown to have strong ACE inhibitory activity. Moreover, tripeptides with L, C or P also exhibit strong ACE inhibitory activity. It should be noted that peptides with hydrophobic C-terminus amino acids are potent ACE inhibitors. Additionally, peptides with a molecular mass below 2 kDa tend to have higher ACE inhibitory activity due to better absorption and bioavailability [73]. In our study, the peptides obtained with ACE inhibitory active, such as PGL, CF, TF, IL, GL, VF, AW, PL and GL, also had a hydrophobic C-terminus residue (Table 1). Similar results were obtained by Elisha et al., where peptides obtained from cow’s and human milk lactoferrin exhibiting diepeptyl peptidase IV inhibitory activity had the sequences GF, GL, AF, SF, and GAL. In the case of bovine, the peptides PF, PL, GL, VF, and GAL showed potential. Furthermore, the sequences YL, CL, CAL, GR, CR, and CSTSPL were common to both lactoferrin from cow and human milk [62].
Plant-derived peptides interact with the human immune system through various mechanisms, including immunomodulation and anti-inflammatory activities. Plant-derived peptides exhibit significant anti-inflammatory properties through various mechanisms. These peptides can modulate inflammatory responses by interacting with specific cellular pathways and molecules [74,75,76]. Plant peptides can reduce the levels of pro-inflammatory cytokines such as IL-6, IL-1β, and TNF-α [75,77,78,79]. This reduction helps in mitigating inflammation and its associated symptoms. These peptides promote the polarization of macrophages to the M2 phenotype, which is associated with anti-inflammatory effects. This shift in a macrophage phenotype helps in resolving inflammation. Many plant-derived peptides inhibit the NF-κB signaling pathway, which plays a crucial role in the inflammatory response. By down-regulating NF-κB, these peptides reduce the expression of inflammatory mediator enzymes, such as cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) [78,80]. Moreover, they can inhibit lipoxygenase (LOX) involved in arachidonic acid metabolism [80]. Plant peptides interfere with the metabolism of arachidonic acid, thereby reducing the production of pro-inflammatory eicosanoids. This mechanism is crucial in controlling inflammation at the molecular level. Some plant peptides can bind to lipopolysaccharides (LPS), neutralizing their inflammatory effects. This binding reduces the recognition of LPS by immune cells, thereby attenuating the inflammatory response [78].
To test the potential use of the peptides obtained as compounds that could be transported in the small intestine to their target sites, their resistance to microbial enzymes was tested in silico. The peptides were hydrolyzed using oligopeptidase F and proteinase P1. This process was also conducted using the BIOPEP databases. The results indicate that not all peptides with specific functions are stable to the action of these enzymes (Table 2). Unstable peptides, on the other hand, can be a good source of free amino acids essential for proper body function [81]. Furthermore, these peptides primarily release exogenous amino acids (essential amino acids), which are not produced in the body and must be supplied through food [82]. It should also be noted that these peptides release proline, which is considered a relatively essential amino acid, the demand for which increases during periods of illness or severe stress [83,84]. This creates the possibility of producing new preparations or dietary supplements that would contain these peptides.
Proteolytic instability is one of the key features of peptides and peptide-containing products, which determines their use in the production of food, dietary supplements or pharmacological compounds. Research is underway to increase their resistance to peptidases/proteinases or to enhance their stability in plasma or serum. These methods most often involve chemical or physical modification, and are often labor-intensive and cost-prohibitive. Therefore, understanding the chemical properties of peptides that influence their degradation facilitates modifications intended to increase their stability. One of the important features of peptides in this context is the determination of the peptide half-life (t ½), which is usually quite short and ranges from 2 to 20 min. Some studies show, however, that the t ½ of these compounds can be even more than 300 min [85]. Extending the half-life of biologically active peptides increases their stability, bioavailability, and applicability. There is no database of peptide half-lives, so these values must be determined experimentally [86].
Moreover, one of the peptides (IL) obtained has neuropeptide properties. Neuropeptides are involved in numerous biological processes, including neurotransmission, neuromodulation, and hormonal regulation. They control functions like cardiovascular activity, energy homeostasis, reproduction, growth, behavior, and stress response [54].
One of the key stages in peptide research is physicochemical analysis, which employs various techniques and methods to determine properties of peptides and possible applications in various fields, including diagnostics, food technology, biotechnology, drug development, and proteomics [87,88]. In this study, the following peptide characteristics were determined: the Boman index, net charge, isoelectric point, instability index, aliphatic index, GRAV, and water solubility (Table 3). By determining the physicochemical properties of peptides, we can also infer their potential bioavailability. Peptides with short chains consisting of two or three amino acids will demonstrate greater bioavailability than those containing more amino acids. Moreover, peptides characterized by high solubility potentially have higher bioavailability than those that are insoluble [86,89].
The Boman index is a measure used to predict the potential biological activity of peptides, particularly their ability to bind to membranes or other proteins as receptors. It is expressed in kcal/mol, and it is calculated from the sum of free energies of the amino acid residues in a peptide sequence. Molecules have high binding potential if the BI is higher than 2.48 [90]. This is supported by research results concerning the arginine-rich cationic peptide SM-985 from teosinte (Zea mays spp. mexicana), whose microbial activity has been verified for six species, and its Boman index was 5.19 kcal/mol [91]. In our study, peptides with the sequence AR, EK, ER, PK, SK, and QH have high potential for binding into a protein or receptor. It should be noted that ten amino acids—A, Cys, Gly, His, Ile, Lys, Leu, Pro, Arg, and Val—are often observed in AMPs [92]. As can be seen from the presented data, peptides with the sequence PGL, IL, GL, IY, VF, PL, IM and QL are characterized by high thermostability because the instability index is higher than 100. This is because these dipeptides contain hydrophobic amino acids. Thermostable peptides can have many applications, especially in chemical analysis, food and pharmaceutical industries, and also in agriculture and environmental protection. Thermostable peptides can be engineered to respond to environmental stimuli, such as temperature, pH, and ionic strength, making them versatile for different applications [93]. Moreover, thermostable AMPs have been designed to maintain their activity under high temperatures and varying pH levels. These peptides can be used in food preservation to inhibit bacterial growth, ensuring food safety and extending shelf life [94]. Additionally, compounds can pose analytical challenges due to their in vitro stability. In order to address this issue, their instability index is determined.
In this study, only two peptides were determined as unstable. They are the peptides with the sequence TF, IL and PF. These dipeptides are composed of hydrophobic amino acids and are poorly soluble in water, so they may not be easy research material in an aqueous environment. The GRAVY index may define the overall hydropathy of a peptide. In this study, the peptides with the sequence AR, EK, ER, PK, TW, PW, SK and QH were characterized by a negative GRAVY index, which indicated their hydrophilic character, meaning that they interact well with water and are likely to be soluble in aqueous environments. Understanding this index helps to predict protein behavior in different environments and can aid in such applications as drug design and protein engineering. Filleria et al. ([95] reported that hydrophobicity may help to increase the antioxidant activity. In their study, the linear sequence of each peptide is observed as well as their variations and a putative relationship with the antioxidant activity. P2 is the only peptide that presents a hydrophobic character according to the GRAVY parameter and has the highest ASAH. P1, P5 and P8 are hydrophilic in agreement with their proportion of ASAP [95]. Understanding the physicochemical properties of peptides can contribute to their increased use in anticancer therapy. Many methods exist for selectively targeting and destroying cancer cells, both proliferative and non-proliferative ones, while bypassing healthy cells. One of these methods is using lipid membranes as an alternative therapeutic target. By disrupting the cancer cell membrane or allowing various compounds to penetrate the cell membrane, they can induce selective cancer cell death. During cancer development, cell membranes undergo changes. It is worth noting that the cell membrane of cancer cells differs from that of non-cancerous cells. The lipid bilayer of healthy cell membranes is characterized by an asymmetric distribution of lipids. The use of cell membranes as a potential therapeutic target is related to the anticancer activity of host defense peptides. A key role is played by cationic amphipathic membrane peptides, which directly target cancer cells by binding to their negatively charged surfaces through electrostatic interactions. Peptides integrate into the hydrophobic core of the cancer cell membrane through polar and nonpolar peptide-lipid interactions. Some peptides at nanomolar concentrations can penetrate the cell membrane and cause cancer cell death. However, at higher concentrations (in the micromolar range), they disrupt the lipid bilayer, often killing cells within an hour [96,97]. That is why it is so important to know the structure and properties of biologically active peptides in order to use them in various therapeutic activities.

4. Materials and Methods

The material for the study was composed of 57 plant peptides (Table 4) with anticancer properties that were selected from the Antimicrobial Peptide Database (https://aps.unmc.edu/home access date 10 September 2025).

4.1. In Silico Enzymatic Hydrolysis

4.1.1. Hydrolysis with Gastrointestinal Track Enzymes

The selected peptides were hydrolyzed using BIOPEP-UWM™ database tools [98] with pepsin (EC 3.4.23.1), trypsin (EC 3.4.21.4), and chymotrypsin (EC 3.4.21.1).

4.1.2. Hydrolysis with Microbial Enzymes

Peptides with biological activity were in silico hydrolyzed with oligopeptidase F and proteinase P1 (EC 3.4.21.96). These enzymes were produced by gastrointestinal track microorganisms.

4.2. Analysis of the Physicochemical Characteristics of Bioactive Peptides

The physicochemical characteristics of peptides were predicted with online tools. The Boman index was estimated by the Antimicrobial Peptide Designer (https://aps.unmc.edu/, access data 10 September 2025); net charge and water solubility were calculated using the peptide property calculator available on https://pepcalc.com/. access data 10 September 2025. The Protein IQ tool (https://proteiniq.io/tools#protein-tools access data 10 September 2025) was used to estimate theoretical isoelectric point (TpI), instability index, aliphatic index and grand average of hydropathicity index (GRAVY).

5. Conclusions

In silico methods have become essential tools in the study and prediction of the biological properties of peptides. These computational approaches offer significant advantages in terms of cost and time efficiency compared to traditional experimental methods. In this study, 57 plant peptides with anticancer properties selected from the Antimicrobial Peptide Database (https://aps.unmc.edu/home, access on 10 September 2025) were hydrolyzed using BIOPEP-UWM™ database tools with pepsin (EC 3.4.23.1), trypsin (EC 3.4.21.4), and chymotrypsin (EC 3.4.21.1). Most peptides obtained after in silico hydrolysis had properties inhibiting ACE and dipeptidyl peptidase IV activity. Some peptides have previously unknown properties, like inhibitory activities towards DPP III (TF, PF and GF), lactocepin (PL), neprilysin (AR), acylaminoacyl peptidase and TPP II (AR). Moreover, one of the peptides (IL) has neuropeptide properties. The use of these peptides that are resistant to the action of proteolytic enzymes of microbial origin seems promising. Further research and development are needed to overcome bioavailability challenges and validate the clinical efficacy of peptides. Research should be based on in vitro studies, i.e., enzymatic hydrolysis of the selected peptides using pepsin, trypsin, and chymotrypsin. Subsequent purification and characterization of the peptides should follow, prior to their application in the design of food products, dietary supplements, or therapeutic formulas. Further in vivo studies are necessary for this purpose. The presented research results serve as a prelude to further analyses and can provide an overview of the research material for obtaining and characterizing biologically active peptides. Owing to their origin and physicochemical properties, biologically active peptides may find application in the creation of new foods or dietary supplements with therapeutic properties. Many peptides act directly as drugs, mimicking natural hormones, enzymes, or ligands (e.g., insulin, GLP-1 analogues, calcitonin). Others can be attached to drugs or nanoparticles to improve transport to tissues or receptors (e.g., RGD-motif peptides for targeting integrins in tumors). Some peptides (cell-penetrating peptides, CPPs) facilitate drug transport across biological barriers, such as the blood–brain barrier or cell membranes. Peptides can act as excipients, stabilizing proteins, preventing their aggregation, or improving solubility in formulations.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms26189189/s1.

Author Contributions

Conceptualization, A.J.; methodology, A.J.; software, A.J.; validation, A.J.; formal analysis, A.J., A.G. and K.R.-T.; data curation, A.J., A.G. and K.R.-T.; writing—original draft preparation, A.J., A.G. and K.R.-T.; writing—review and editing, A.J., A.G. and K.R.-T.; visualization, A.J.; supervision, A.J. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

During the preparation of this manuscript/study, the authors used Scopus AI for the purposes of a literature study. The authors have reviewed and edited the output and take full responsibility for the content of this publication.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
TPP IITripeptidyl peptidase II
DPP IIIDipeptidyl peptidase-III
LPSLipopolysaccharides
LOXLipoxygenase
iNOSNitric oxide synthase
COX-2Cyclooxygenase
RAASRenin–angiotensin–aldosterone system
NONitric oxide
PTPN18Protein tyrosine phosphatase non-receptor type 18
NF-κBNuclear factor kappa-light-chain-enhancer of activated B cells
RASRenin-angiotensin system
NLSNuclear localization sequences
ACE2Angiotensin-converting enzyme 2
ACEAngiotensin-converting enzyme
FAKFocal adhesion kinase
NSCLCNon-small-cell lung cancer
RBRetinoblastoma
p27Kip1Cyclin-dependent kinase inhibitor 1B
MCoTI-IIA native cyclotide
AMPDAntimicrobial peptide database
AMPsAntibacterial plant-derived peptides
ROSReactive oxygen species
VEGF-AVascular endothelial growth factor A

References

  1. Salas, C.E.; Badillo-Corona, J.A.; Ramírez-Sotelo, G.; Oliver-Salvador, C. Biologically Active and Antimicrobial Peptides from Plants. BioMed Res. Int. 2015, 2015, 102129. [Google Scholar] [CrossRef]
  2. Sharma, V.; Gupta, P.; Sharma, P. Recent Advancements in Novel Bioactive Peptides and Protein Hydrolysates Isolated from Different Medicinal Plants Along with Their Applications in Food and Pharmaceutical Industries; Springer: Dordrecht, The Netherlands, 2023; Volume 29, ISBN 0123456789. [Google Scholar]
  3. Zhu, F.; Cao, J.; Song, Y.; Yu, P.; Su, E. Plant Protein-Derived Active Peptides: A Comprehensive Review. J. Agric. Food Chem. 2023, 71, 20479–20499. [Google Scholar] [CrossRef]
  4. Mani, S.; Bhatt, S.B.; Vasudevan, V.; Prabhu, D.; Rajamanikandan, S.; Velusamy, P.; Ramasamy, P.; Raman, P. The Updated Review on Plant Peptides and Their Applications in Human Health; Springer: Dordrecht, The Netherlands, 2022; Volume 28, ISBN 0123456789. [Google Scholar]
  5. Liu, M.; Huang, X.; Wu, H.; Wen, L.; Cheng, Y.; Chen, M. Screening of Antimicrobial Peptides from Plants and Their Application in Food. Food Mach. 2024, 40, 200–207+215. [Google Scholar] [CrossRef]
  6. Wu, H.; Yu, B.; Cong, H. Preparation and Applications of Antimicrobial Peptides. In Peptide Nano-Chemistry and Nanotechnology: From Molecular Design, Self-Assembly, Biomimetic Synthesis to Applications; Springer: Singapore, 2025; pp. 205–225. [Google Scholar]
  7. Ghanbarzadeh, Z.; Mohagheghzadeh, A.; Hemmati, S. The Roadmap of Plant Antimicrobial Peptides Under Environmental Stress: From Farm to Bedside. Probiotics Antimicrob. Proteins 2024, 16, 2269–2304. [Google Scholar] [CrossRef]
  8. Lu, Y.; Tian, H.; Chen, R.; Liu, Q.; Jia, K.; Hu, D.-L.; Chen, H.; Ye, C.; Peng, L.; Fang, R. Synergistic Antimicrobial Effect of Antimicrobial Peptides CATH-1, CATH-3, and PMAP-36 with Erythromycin Against Bacterial Pathogens. Front. Microbiol. 2022, 13, 953720. [Google Scholar] [CrossRef] [PubMed]
  9. Bucataru, C.; Ciobanasu, C. Antimicrobial Peptides: Opportunities and Challenges in Overcoming Resistance. Microbiol. Res. 2024, 286, 127822. [Google Scholar] [CrossRef]
  10. Chai, K.F.; Voo, A.Y.H.; Chen, W.N. Bioactive Peptides from Food Fermentation: A Comprehensive Review of Their Sources, Bioactivities, Applications, and Future Development. Compr. Rev. Food Sci. Food Saf. 2020, 19, 3825–3855. [Google Scholar] [CrossRef]
  11. Luo, X.; Wu, W.; Feng, L.; Treves, H.; Ren, M. Short Peptides Make a Big Difference: The Role of Botany-Derived Amps in Disease Control and Protection of Human Health. Int. J. Mol. Sci. 2021, 22, 11363. [Google Scholar] [CrossRef]
  12. Lima, A.M.; Azevedo, M.I.G.; Sousa, L.M.; Oliveira, N.S.; Andrade, C.R.; Freitas, C.D.T.; Souza, P.F.N. Plant Antimicrobial Peptides: An Overview about Classification, Toxicity and Clinical Applications. Int. J. Biol. Macromol. 2022, 214, 10–21. [Google Scholar] [CrossRef] [PubMed]
  13. Gelinski, J.M.L.N.; de Melo Franco, B.D.G.; Fonseca, G.G. Plant-Derived Antimicrobial Peptides. In Antimicrobial Peptides: Challenges and Future Perspectives; Academic Press: Cambridge, MA, USA, 2022; pp. 157–169. [Google Scholar]
  14. Abbas, S.K.; Qadeer, S.; Khan, M.J.; Abbas, S.T.; Shah, N.A. Plant-Based Peptides: Antibiotics. In Recent Advances in Industrial Biochemistry; Springer: Cham, Switzerland, 2024; pp. 77–91. [Google Scholar]
  15. Zou, F.; Tan, C.; Shinali, T.S.; Zhang, B.; Zhang, L.; Han, Z.; Shang, N. Plant Antimicrobial Peptides: A Comprehensive Review of Their Classification, Production, Mode of Action, Functions, Applications, and Challenges. Food Funct. 2023, 14, 5492–5515. [Google Scholar] [CrossRef] [PubMed]
  16. Chen, X.; Song, M.; Tian, L.; Shan, X.; Mao, C.; Chen, M.; Zhao, J.; Sami, A.; Yin, H.; Ali, U.; et al. A Plant Peptide with Dual Activity against Multidrug-Resistant Bacterial and Fungal Pathogens. Sci. Adv. 2025, 11, eadt8239. [Google Scholar] [CrossRef]
  17. Mishra, J.; Rajput, R.; Singh, K.; Puri, S.; Goyal, M.; Bansal, A.; Misra, K. Antibacterial Natural Peptide Fractions from Indian Ganoderma Lucidum. Int. J. Pept. Res. Ther. 2018, 24, 543–554. [Google Scholar] [CrossRef]
  18. Chai, T.-T.; Tan, Y.-N.; Ee, K.-Y.; Xiao, J.; Wong, F.-C. Seeds, Fermented Foods, and Agricultural by-Products as Sources of Plant-Derived Antibacterial Peptides. Crit. Rev. Food Sci. Nutr. 2019, 59, S162–S177. [Google Scholar] [CrossRef]
  19. Feyzyab, H.; Fathi, N.; Bolhassani, A. Antiviral Peptides Derived from Plants: Their Designs and Functions. Protein Pept. Lett. 2023, 30, 975–985. [Google Scholar] [CrossRef]
  20. Feijoo-Coronel, M.L.; Mendes, B.; Ramírez, D.; Peña-Varas, C.; de los Monteros-Silva, N.Q.E.; Proaño-Bolaños, C.; de Oliveira, L.C.; Lívio, D.F.; da Silva, J.A.; da Silva, J.M.S.F.; et al. Antibacterial and Antiviral Properties of Chenopodin-Derived Synthetic Peptides. Antibiotics 2024, 13, 78. [Google Scholar] [CrossRef] [PubMed]
  21. Singh, D.; Dhiman, V.K.; Pandey, M.; Dhiman, V.K.; Sharma, A.; Pandey, H.; Verma, S.K.; Pandey, R. Personalized Medicine: An Alternative for Cancer Treatment. Cancer Treat. Res. Commun. 2024, 42, 100860. [Google Scholar] [CrossRef]
  22. Rituraj; Pal, R.S.; Wahlang, J.; Pal, Y.; Chaitanya, M.V.N.L.; Saxena, S. Precision Oncology: Transforming Cancer Care through Personalized Medicine. Med. Oncol. 2025, 42, 246. [Google Scholar] [CrossRef]
  23. Mao, Y.; Shangguan, D.; Huang, Q.; Xiao, L.; Cao, D.; Zhou, H.; Wang, Y.K. Emerging Artificial Intelligence-Driven Precision Therapies in Tumor Drug Resistance: Recent Advances, Opportunities, and Challenges. Mol. Cancer 2025, 24, 123. [Google Scholar] [CrossRef]
  24. He, W.; McCoy, M.D.; Riggins, R.B.; Beckman, R.A.; Yeang, C.H. Personalized Cancer Treatment Strategies Incorporating Irreversible and Reversible Drug Resistance Mechanisms. npj Syst. Biol. Appl. 2025, 11, 70. [Google Scholar] [CrossRef] [PubMed]
  25. Dong, Z.; Zhang, X.; Zhang, Q.; Tangthianchaichana, J.; Guo, M.; Du, S.; Lu, Y. Anticancer Mechanisms and Potential Anticancer Applications of Antimicrobial Peptides and Their Nano Agents. Int. J. Nanomed. 2024, 19, 1017–1039. [Google Scholar] [CrossRef] [PubMed]
  26. Yang, M.; Liu, S.; Zhang, C. Antimicrobial Peptides with Antiviral and Anticancer Properties and Their Modification and Nanodelivery Systems. Curr. Res. Biotechnol. 2023, 5, 100121. [Google Scholar] [CrossRef]
  27. Zare-Zardini, H.; Saberian, E.; Jenča, A.; Ghanipour-Meybodi, R.; Petrášová, A.; Jenčová, J. From Defense to Offense: Antimicrobial Peptides as Promising Therapeutics for Cancer. Front. Oncol. 2024, 14, 1463088. [Google Scholar] [CrossRef]
  28. Guzmán-Rodríguez, J.J.; Ochoa-Zarzosa, A.; López-Gómez, R.; López-Meza, J.E. Plant Antimicrobial Peptides as Potential Anticancer Agents. BioMed Res. Int. 2015, 2015, 735087. [Google Scholar] [CrossRef]
  29. Flores-Alvarez, L.J.; Jiménez-Alcántar, P.; Ochoa-Zarzosa, A.; López-Meza, J.E. The Antimicrobial Peptide γ-Thionin from Habanero Chile (Capsicum chinense) Induces Caspase-Independent Apoptosis on Human K562 Chronic Myeloid Leukemia Cells and Regulates Epigenetic Marks. Molecules 2023, 28, 3661. [Google Scholar] [CrossRef]
  30. Qu, H.; Smithies, B.J.; Durek, T.; Craik, D.J. Synthesis and Protein Engineering Applications of Cyclotides. Aust. J. Chem. 2017, 70, 152–161. [Google Scholar] [CrossRef]
  31. Mehta, L.; Dhankhar, R.; Gulati, P.; Kapoor, R.K.; Mohanty, A.; Kumar, S. Natural and Grafted Cyclotides in Cancer Therapy: An Insight. J. Pept. Sci. 2020, 26, e3246. [Google Scholar] [CrossRef]
  32. Ghadiri, N.; Javidan, M.; Sheikhi, S.; Taştan, Ö.; Parodi, A.; Liao, Z.; Tayybi Azar, M.; Ganjalıkhani-Hakemi, M. Bioactive Peptides: An Alternative Therapeutic Approach for Cancer Management. Front. Immunol. 2024, 15, 1310443. [Google Scholar] [CrossRef] [PubMed]
  33. Gunasekera, S.; Foley, F.M.; Clark, R.J.; Sando, L.; Fabri, L.J.; Craik, D.J.; Daly, N.L. Engineering Stabilized Vascular Endothelial Growth Factor-A Antagonists: Synthesis, Structural Characterization, and Bioactivity of Grafted Analogues of Cyclotides. J. Med. Chem. 2008, 51, 7697–7704. [Google Scholar] [CrossRef] [PubMed]
  34. Huang, Y.H.; Henriques, S.T.; Wang, C.K.; Thorstholm, L.; Daly, N.L.; Kaas, Q.; Craik, D.J. Design of Substrate-Based BCR-ABL Kinase Inhibitors Using the Cyclotide Scaffold. Sci. Rep. 2015, 5, 12974. [Google Scholar] [CrossRef] [PubMed]
  35. Maaß, F.; Wüstehube-Lausch, J.; Dickgießer, S.; Valldorf, B.; Reinwarth, M.; Schmoldt, H.U.; Daneschdar, M.; Avrutina, O.; Sahin, U.; Kolmar, H. Cystine-Knot Peptides Targeting Cancer-Relevant Human Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4). J. Pept. Sci. 2015, 21, 651–660. [Google Scholar] [CrossRef]
  36. Henriques, S.T.; Huang, Y.H.; Chaousis, S.; Sani, M.A.; Poth, A.G.; Separovic, F.; Craik, D.J. The Prototypic Cyclotide Kalata B1 Has a Unique Mechanism of Entering Cells. Chem. Biol. 2015, 22, 1087–1097. [Google Scholar] [CrossRef]
  37. Inaba, J.; McConnell, E.J.; Davis, K.R. Lunasin Sensitivity in Non-Small Cell Lung Cancer Cells Is Linked to Suppression of Integrin Signaling and Changes in Histone Acetylation. Int. J. Mol. Sci. 2014, 15, 23705–23724. [Google Scholar] [CrossRef] [PubMed]
  38. McConnell, E.J.; Devapatla, B.; Yaddanapudi, K.; Davis, K.R. The Soybean-Derived Peptide Lunasin Inhibits Non-Small Cell Lung Cancer Cell Proliferation by Suppressing Phosphorylation of the Retinoblastoma Protein. Oncotarget 2015, 6, 4649–4662. [Google Scholar] [CrossRef] [PubMed]
  39. Shidal, C.; Inaba, J.I.; Yaddanapudi, K.; Davis, K.R. The Soy-Derived Peptide Lunasin Inhibits Invasive Potential of Melanoma Initiating Cells. Oncotarget 2017, 8, 25525–25541. [Google Scholar] [CrossRef] [PubMed]
  40. Kim, B.J.; Xu, B. Enzyme-Instructed Self-Assembly for Cancer Therapy and Imaging. Bioconjug. Chem. 2020, 31, 492–500. [Google Scholar] [CrossRef]
  41. Qin, H.; Ding, Y.; Mujeeb, A.; Zhao, Y.; Nie, G. Tumor Microenvironment Targeting and Responsive Peptide-Based Nanoformulations for Improved Tumor Therapy. Mol. Pharmacol. 2017, 92, 219–231. [Google Scholar] [CrossRef]
  42. Shi, J.; Xu, B. Nanoscale Assemblies of Small Molecules Control the Fate of Cells. Nano Today 2015, 10, 615–630. [Google Scholar] [CrossRef]
  43. Chen, C.H.; Bepler, T.; Pepper, K.; Fu, D.; Lu, T.K. Synthetic Molecular Evolution of Antimicrobial Peptides. Curr. Opin. Biotechnol. 2022, 75, 102718. [Google Scholar] [CrossRef]
  44. Guo, H.; Richel, A.; Hao, Y.; Fan, X.; Everaert, N.; Yang, X.; Ren, G. Novel Dipeptidyl Peptidase-IV and Angiotensin-I-Converting Enzyme Inhibitory Peptides Released from Quinoa Protein by in Silico Proteolysis. Food Sci. Nutr. 2020, 8, 1415–1422. [Google Scholar] [CrossRef]
  45. Hogarth, C.A.; Calanni, S.; Jans, D.A.; Loveland, K.L. Importin α MRNAs Have Distinct Expression Profiles during Spermatogenesis. Dev. Dyn. 2006, 235, 253–262. [Google Scholar] [CrossRef]
  46. Wang, T.; Ba, X.; Zhang, X.; Zhang, N.; Wang, G.; Bai, B.; Li, T.; Zhao, J.; Zhao, Y.; Yu, Y.; et al. Nuclear Import of PTPN18 Inhibits Breast Cancer Metastasis Mediated by MVP and Importin Β2. Cell Death Dis. 2022, 13, 720. [Google Scholar] [CrossRef]
  47. Mahipal, A.; Malafa, M. Importins and Exportins as Therapeutic Targets in Cancer. Pharmacol. Ther. 2016, 164, 135–143. [Google Scholar] [CrossRef]
  48. Kao, H.J.; Weng, T.H.; Chen, C.H.; Chen, Y.C.; Chi, Y.H.; Huang, K.Y.; Weng, S.L. Integrating In Silico and In Vitro Approaches to Identify Natural Peptides with Selective Cytotoxicity against Cancer Cells. Int. J. Mol. Sci. 2024, 25, 6848. [Google Scholar] [CrossRef]
  49. Radchenko, T.; Brink, A.; Siegrist, Y.; Kochansky, C.; Bateman, A.; Fontaine, F.; Morettoni, L.; Zamora, I. Software-Aided Approach to Investigate Peptide Structure and Metabolic Susceptibility of Amide Bonds in Peptide Drugs Based on High Resolution Mass Spectrometry. PLoS ONE 2017, 12, e0186461. [Google Scholar] [CrossRef]
  50. Iwaniak, A.; Darewicz, M.; Mogut, D.; Minkiewicz, P. Elucidation of the Role of in Silico Methodologies in Approaches to Studying Bioactive Peptides Derived from Foods. J. Funct. Foods 2019, 61, 103486. [Google Scholar] [CrossRef]
  51. Zhu, Z.; Li, R.; Yuan, Z.; Xue, Y. Mechanism, Preparation, Evaluation and Related Research Progress of Plant-Derived Antihypertensive Peptides. Sci. Technol. Food Ind. 2022, 43, 501–508. [Google Scholar] [CrossRef]
  52. Anón, M.C.; Quiroga, A.; Scilingo, A.; Tironi, V. Plant Bioactive Peptides: From Oilseed, Legume, Cereal, Fruit, and Vegetable. In Handbook of Food Bioactive Ingredients: Properties and Applications; Springer: Cham, Switzerland, 2023; pp. 907–940. [Google Scholar]
  53. Mackraj, I.; Govender, T.; Ramesar, S. The Antihypertensive Effects of Quercetin in a Salt-Sensitive Model of Hypertension. J. Cardiovasc. Pharmacol. 2008, 51, 239–245. [Google Scholar] [CrossRef] [PubMed]
  54. Sharma, D.; Kumar, K.; Bisht, G.S. A Mini-Review on Potential of Neuropeptides as Future Therapeutics. Int. J. Pept. Res. Ther. 2022, 28, 39. [Google Scholar] [CrossRef]
  55. Li, X.; Zuo, S.; Wang, B.; Zhang, K.; Wang, Y. Antimicrobial Mechanisms and Clinical Application Prospects of Antimicrobial Peptides. Molecules 2022, 27, 2675. [Google Scholar] [CrossRef]
  56. Rivera del Rio, A.; van der Wielen, N.; Gerrits, W.J.J.; Boom, R.M.; Janssen, A.E.M. In Silico Modelling of Protein Digestion: A Case Study on Solid/Liquid and Blended Meals. Food Res. Int. 2022, 157, 111271. [Google Scholar] [CrossRef]
  57. Huang, Y.; Chen, Y.; Lu, S.; Zhao, C. Recent Advance of in Vitro Models in Natural Phytochemicals Absorption and Metabolism. eFood 2021, 2, 307–318. [Google Scholar] [CrossRef] [PubMed]
  58. Xin, M.; Zhao, M.; Tian, J.; Li, B. Guidelines for in Vitro Simulated Digestion and Absorption of Food. Food Front. 2023, 4, 524–532. [Google Scholar] [CrossRef]
  59. McFarland, C.; Alkotaini, B.; Cowen, C.P.; Edwards, M.G.; Grein, E.; Hahn, A.D.; Jennings, J.C.; Patnaik, R.; Potter, S.M.; Rael, L.T.; et al. Discovery, Expression, and In Silico Safety Evaluation of Honey Truffle Sweetener, a Sweet Protein Derived from Mattirolomyces Terfezioides and Produced by Heterologous Expression in Komagataella Phaffii. J. Agric. Food Chem. 2024, 72, 19470–19479. [Google Scholar] [CrossRef]
  60. Freeman, E.L.; Ward, R.; Murphy, M.M.; Wang, T.; Ryder, J. Comprehensive Safety Assessment of Serendipity Berry Sweet Protein Produced from Komagataella Phaffii. Regul. Toxicol. Pharmacol. 2024, 147, 105562. [Google Scholar] [CrossRef]
  61. López-Ibarra, C.; Ruiz-López, F.d.J.; Bautista-Villarreal, M.; Báez-González, J.G.; Rodríguez Romero, B.A.; González-Martínez, B.E.; López-Cabanillas Lomelí, M.; Vázquez-Rodríguez, J.A. Protein Concentrates on Tepary Bean (Phaseolus acutifolius Gray) as a Functional Ingredient: In Silico Docking of Tepary Bean Lectin to Peroxisome Proliferator-Activated Receptor Gamma. Front. Nutr. 2021, 8, 661463. [Google Scholar] [CrossRef]
  62. Elisha, C.; Bhagwat, P.; Pillai, S. In Silico and in Vitro Analysis of Dipeptidyl Peptidase-IV and Angiotensin-Converting Enzyme Inhibitory Peptides Derived from Milk Lactoferrin. Int. Dairy J. 2025, 160, 106092. [Google Scholar] [CrossRef]
  63. Nirmal, N.; Khanashyam, A.C.; Shah, K.; Awasti, N.; Sajith Babu, K.; Ucak, İ.; Afreen, M.; Hassoun, A.; Tuanthong, A. Plant Protein-Derived Peptides: Frontiers in Sustainable Food System and Applications. Front. Sustain. Food Syst. 2024, 8, 1292297. [Google Scholar] [CrossRef]
  64. Wen, C.; Zhang, J.; Zhang, H.; Duan, Y.; Ma, H. Plant Protein-Derived Antioxidant Peptides: Isolation, Identification, Mechanism of Action and Application in Food Systems: A Review. Trends Food Sci. Technol. 2020, 105, 308. [Google Scholar] [CrossRef]
  65. Zhu, Z.; Xu, Z.; Li, Y.; Fan, Y.; Zhou, Y.; Song, K.; Meng, L. Antioxidant Function and Application of Plant-Derived Peptides. Antioxidants 2024, 13, 1203. [Google Scholar] [CrossRef]
  66. Wong, F.-C.; Xiao, J.; Wang, S.; Ee, K.-Y.; Chai, T.-T. Advances on the Antioxidant Peptides from Edible Plant Sources. Trends Food Sci. Technol. 2020, 99, 44–57. [Google Scholar] [CrossRef]
  67. Nwachukwu, I.D.; Aluko, R.E. Structural and Functional Properties of Food Protein-derived Antioxidant Peptides. J. Food Biochem. 2019, 43, e12761. [Google Scholar] [CrossRef] [PubMed]
  68. Aguilar, J.G.S. Plant-Based Peptides with Biological Properties. In Phytopharmaceuticals: Potential Therapeutic Applications; Wiley-Scrivener: Austin, TX, USA, 2021; pp. 123–134. [Google Scholar]
  69. Ali, A.; Bukhsh, K.K.; Raza, M.M.; Afraz, M.T.; Diana, T.; Waseem, M.; Manzoor, M.F.; Abdi, G. Exploring the Structure–Activity Relationships and Molecular Mechanisms of Food-Derived Antioxidative Peptides in Mitigating Oxidative Stress: A Comprehensive Review. J. Funct. Foods 2025, 127, 106751. [Google Scholar] [CrossRef]
  70. Apone, F.; Barbulova, A.; Colucci, M.G. Plant and Microalgae Derived Peptides Are Advantageously Employed as Bioactive Compounds in Cosmetics. Front. Plant Sci. 2019, 10, 756. [Google Scholar] [CrossRef]
  71. Shukla, P.; Chopada, K.; Sakure, A.; Hati, S. Current Trends and Applications of Food-Derived Antihypertensive Peptides for the Management of Cardiovascular Disease. Protein Pept. Lett. 2022, 29, 408–428. [Google Scholar] [CrossRef]
  72. Fan, H.; Liu, H.; Zhang, Y.; Zhang, S.; Liu, T.; Wang, D. Review on Plant-Derived Bioactive Peptides: Biological Activities, Mechanism of Action and Utilizations in Food Development. J. Futur. Foods 2022, 2, 143. [Google Scholar] [CrossRef]
  73. Ding, Q.; Sheikh, A.R.; Chen, Q.; Hu, Y.; Sun, N.; Su, X.; Luo, L.; Ma, H.; He, R. Understanding the Mechanism for the Structure-Activity Relationship of Food-Derived ACEI Peptides. Food Rev. Int. 2023, 39, 1751–1769. [Google Scholar] [CrossRef]
  74. Rupachandra, S.; Porkodi, S.; Joann, M.D.; Jagadeeshwari, S. Evaluation of Anti-Inflammatory Efficacy of RA-V: A Natural Cyclopeptide. Appl. Biochem. Biotechnol. 2020, 190, 732–744. [Google Scholar] [CrossRef]
  75. Liu, W.; Chen, X.; Li, H.; Zhang, J.; An, J.; Liu, X. Anti-Inflammatory Function of Plant-Derived Bioactive Peptides: A Review. Foods 2022, 11, 2361. [Google Scholar] [CrossRef]
  76. Malhotra, R.; Rana, N.; Manwatkar, S.; Kumar, B. Application of Peptides for the Treatment of Diabetes: A Plant-Based Bioactive Material. In Biosystems, Biomedical & Drug Delivery Systems Characterization, Restoration and Optimization; Springer: Singapore, 2024; pp. 327–343. [Google Scholar]
  77. de Medeiros, A.F.; de Queiroz, J.L.C.; Maciel, B.L.L.; de Araújo Morais, A.H. Hydrolyzed Proteins and Vegetable Peptides: Anti-Inflammatory Mechanisms in Obesity and Potential Therapeutic Targets. Nutrients 2022, 14, 690. [Google Scholar] [CrossRef] [PubMed]
  78. Han, R.; Hernández Álvarez, A.J.; Maycock, J.; Murray, B.S.; Boesch, C. Differential Effects of Oilseed Protein Hydrolysates in Attenuating Inflammation in Murine Macrophages. Food Biosci. 2022, 49, 101860. [Google Scholar] [CrossRef]
  79. Barragan-Galvez, J.C.; Gonzalez-Rivera, M.L.; Jiménez-Cruz, J.C.; Hernandez-Flores, A.; de la Rosa, G.; Lopez-Moreno, M.L.; Yañez-Barrientos, E.; Romero-Hernández, M.; Deveze-Alvarez, M.A.; Navarro-Santos, P.; et al. A Patent-Pending Ointment Containing Extracts of Five Different Plants Showed Antinociceptive and Anti-Inflammatory Mechanisms in Preclinical Studies. Pharmaceutics 2024, 16, 1215. [Google Scholar] [CrossRef] [PubMed]
  80. Nworu, C.S.; Akah, P.A. Anti-Inflammatory Medicinal Plants and the Molecular Mechanisms Underlying Their Activities. Afr. J. Tradit. Complement. Altern. Med. 2015, 12, 52–61. [Google Scholar] [CrossRef][Green Version]
  81. Bröer, S. Intestinal Amino Acid Transport and Metabolic Health. Annu. Rev. Nutr. 2023, 43, 73–99. [Google Scholar] [CrossRef]
  82. Ewy, M.W.; Patel, A.; Abdelmagid, M.G.; Mohamed Elfadil, O.; Bonnes, S.L.; Salonen, B.R.; Hurt, R.T.; Mundi, M.S. Plant-Based Diet: Is It as Good as an Animal-Based Diet When It Comes to Protein? Curr. Nutr. Rep. 2022, 11, 337–346. [Google Scholar] [CrossRef] [PubMed]
  83. Phang, J.M.; Pandhare, J.; Liu, Y. The Metabolism of Proline as Microenvironmental Stress Substrate. J. Nutr. 2008, 138, 2008S–2015S. [Google Scholar] [CrossRef]
  84. Demir, S.; Bulut, M.; Atli, A.; Kaplan, İ.; Kaya, M.C.; Bez, Y.; Özdemir, P.G.; Sır, A. Decreased Prolidase Activity in Patients with Posttraumatic Stress Disorder. Psychiatry Investig. 2016, 13, 420–426. [Google Scholar] [CrossRef]
  85. Cavaco, M.; Valle, J.; Flores, I.; Andreu, D.; Castanho, M.A.R.B. Estimating Peptide Half-Life in Serum from Tunable, Sequence-Related Physicochemical Properties. Clin. Transl. Sci. 2021, 14, 1349–1358. [Google Scholar] [CrossRef]
  86. Mathur, D.; Singh, S.; Mehta, A.; Agrawal, P.; Raghava, G.P.S. In Silico Approaches for Predicting the Half-Life of Natural and Modified Peptides in Blood. PLoS ONE 2018, 13, e0196829. [Google Scholar] [CrossRef]
  87. Klepach, A.; Tran, H.; Ahmad Mohammed, F.; ElSayed, M.E.H. Characterization and Impact of Peptide Physicochemical Properties on Oral and Subcutaneous Delivery. Adv. Drug Deliv. Rev. 2022, 186, 114322. [Google Scholar] [CrossRef]
  88. Ali, N.; Shamoon, A.; Yadav, N.; Sharma, T. Peptide Combination Generator: A Tool for Generating Peptide Combinations. ACS Omega 2020, 5, 5781–5783. [Google Scholar] [CrossRef]
  89. Alahyaribeik, S.; Mirdamadi, S.; Shim, H.; Cheung, P.C.K.; Wu, J.; Grootaert, C.; Van Camp, J.; Mirzaei, M. Potential Antidiabetic Activity and Permeability Assessment of the Modified Yeast-Derived Peptide, VLSTSFPPW (VW9). Food Chem. 2025, 490, 144968. [Google Scholar] [CrossRef]
  90. Boman, H.G. Antibacterial Peptides: Basic Facts and Emerging Concepts. J. Intern. Med. 2003, 254, 197–215. [Google Scholar] [CrossRef]
  91. Qutb, A.M.; Wei, F.; Dong, W. Prediction and Characterization of Cationic Arginine-Rich Plant Antimicrobial Peptide SM-985 From Teosinte (Zea Mays ssp. Mexicana). Front. Microbiol. 2020, 11, 1353. [Google Scholar] [CrossRef]
  92. Decker, A.P.; Mechesso, A.F.; Wang, G. Expanding the Landscape of Amino Acid-Rich Antimicrobial Peptides: Definition, Deployment in Nature, Implications for Peptide Design and Therapeutic Potential. Int. J. Mol. Sci. 2022, 23, 12874. [Google Scholar] [CrossRef]
  93. Li, Y.; Yang, G.; Gerstweiler, L.; Thang, S.H.; Zhao, C.X. Design of Stimuli-Responsive Peptides and Proteins. Adv. Funct. Mater. 2023, 33, 2210387. [Google Scholar] [CrossRef]
  94. Vishweshwaraiah, Y.L.; Acharya, A.; Hegde, V.; Prakash, B. Rational Design of Hyperstable Antibacterial Peptides for Food Preservation. npj Sci. Food 2021, 5, 26. [Google Scholar] [CrossRef]
  95. Fillería, S.G.; Nardo, A.E.; Paulino, M.; Tironi, V. Peptides Derived from the Gastrointestinal Digestion of Amaranth 11S Globulin: Structure and Antioxidant Functionality. Food Chem. Mol. Sci. 2021, 3, 100053. [Google Scholar] [CrossRef]
  96. Varela-Quitián, Y.F.; Mendez-Rivera, F.E.; Bernal-Estévez, D.A. Cationic Antimicrobial Peptides: Potential Templates for Anticancer Agents. Front. Med. 2025, 12, 1548603. [Google Scholar] [CrossRef] [PubMed]
  97. Lamb, H.O.; Benfield, A.H.; Henriques, S.T. Peptides as Innovative Strategies to Combat Drug Resistance in Cancer Therapy. Drug Discov. Today 2024, 29, 104206. [Google Scholar] [CrossRef] [PubMed]
  98. Minkiewicz, P.; Iwaniak, A.; Darewicz, M. BIOPEP-UWM Database of Bioactive Peptides: Current Opportunities. Int. J. Mol. Sci. 2019, 20, 5978. [Google Scholar] [CrossRef] [PubMed]
Table 1. Peptides obtained after pepsin, trypsin and chymotrypsin in silico hydrolysis.
Table 1. Peptides obtained after pepsin, trypsin and chymotrypsin in silico hydrolysis.
ActivitySequenceSource (AP ID)
ACE inhibitor ARAP00236
PGLAP00984
CF AP00984
EKAP00984, AP02329
TFAP00979
ILAP00979
GLAP01026, AP01124, AP01784, AP01785, AP01806, AP01807,
AP02332, AP02657
IYAP01277, AP01278, AP01279, AP01280, AP01281, AP01282, AP01284, AP01328
ERAP01280, AP01282, AP01284, AP01328
VFAP01343
AWAP01805
PLAP02657
GKAP02328
GFAP05050
Antioxidative PKAP00236
TWAP00236
IYAP01277, AP01278, AP01279, AP01280, AP01281, AP01282, AP01284, AP01328
AWAP01805
PWAP01986, AP01988
Dipeptidyl peptidase IV inhibitor PKAP00236, AP01278, AP01279, AP01280, AP01281, AP01282, AP01284, AP01328
TWAP00236
EKAP00984, AP02329
ILAP00979
TFAP00979
GLAP01026, AP01124, AP01784, AP01785, AP01806, AP01807, AP02332, AP02657
SKAP01036, AP01123, AP01124, AP01774, AP01777, AP01808, AP01813, AP01983, AP02329, AP05050
VFAP01343
AWAP01805
PFAP01985
PWAP01986, AP01988
IMAP02329
QHAP02329
QLAP02329
PLAP02657
GFAP05050
StimulatingILAP00979
Renin inhibitorTFAP00979
Dipeptidyl peptidase III inhibitorTFAP00979
PFAP01985
GFAP05050
NeuropeptideILAP00979
ACE2 inhibitorPFAP01985
Xaa-pro inhibitorPLAP02657
Lactocepin inhibitorPLAP02657
Acylaminoacyl peptidase inhibitorGFAP05050
Tripeptidyl peptidase II inhibitorGFAP05050
Neprilysin inhibitorARAP00236
Table 2. Peptides resistant to hydrolysates of enzymes from microorganism.
Table 2. Peptides resistant to hydrolysates of enzymes from microorganism.
Peptide SequenceOligopeptidase F ActionProteinase P1 Action
ARARAR
PGLPGLP
G
L
CFCFCF
EKEKEK
TFTFTF
ILILI
L
GLGLG
L
IYIYIY
ERERER
VFVFV
F
AWAWAW
PLPLP
L
GFGFGF
GKGKGK
PKPKP
K
TWTWTW
PWPWP
W
SKSKSK
PFPFP
F
IMIMIM
QHQHQ
H
QLQLQ
L
Table 3. Physicochemical characteristic of peptides.
Table 3. Physicochemical characteristic of peptides.
Peptides SequenceIndex Boman (kcal/mol)Net ChargeTheoretical pIInstability IndexAliphatic IndexGRAVYWater Solubility
AR6.55110.555.050−1.35good
PGL−1.9506.106.67130.000.60poor
CF −2.13−0.15.925.002.65poor
EK6.1806.415.00−3.70good
TF−0.206.1066.7001.05poor
IL−4.9206.10101.30390.004.15poor
GL−2.9306.105.0195.001.70poor
IY−2.3906.095.0195.001.60poor
ER10.8606.415.00−4.00good
VF−3.5106.105.0145.003.50poor
AW−2.0706.105.0500.45poor
PL−2.4606.105.0195.001.10poor
GF−1.9606.105.001.20poor
GK2.3006.70−37450−2.15good
PK2.7719.705.00−2.75good
TW0.1106.10−70.150−0.80poor
PW−1.1606.10−9.400−1.25poor
SK4.4719.705.00−2.35good
PF−1.4906.10101.3000.60poor
IM−3.6306.105.0195.003.20poor
QH5.090.17.555.00−3.35good
QL0.3106.105.0195.000.15poor
Table 4. The sequences of plant antimicrobial peptides with anticancer properties.
Table 4. The sequences of plant antimicrobial peptides with anticancer properties.
NoAPD IDNameSourceSequence
1AP00236Pyrularia thioninNuts, Pyrularia puberaKSCCRNTWARNCYNVCRLPGTISREICAKKCDCKIISGTTCPSDYPK
2AP00532LunatusinLima bean Phaseolus lunatus L.KTCENLADTFRGPCFATSNC
3AP00553SesquinGround bean seeds, Vigna sesquipedalisKTCENLADTY
4AP00984TPP3Tomato, Lycopersicon esculentumQICKAPSQTFPGLCFMDSSCRKYCIKEKFTGGHCSKLQRKCLCTKPC
5AP00979NaD1ornamental tobacco flowers, Nicotiana alataRECKTESNTFPGICITKPPCRKACISEKFTDGHCSKILRRCLCTKPC
6AP01026Varv peptide AViola arvensis, Viola odorata, Viola tricolor, Viola baoshanensi, Viola yedoensis, and Viola bifloraGLPVCGETCVGGTCNTPGCSCSWPVCTRN
7AP01031Varv peptide FViola arvensisGVPICGETCTLGTCYTAGCSCSWPVCTRN
8AP01036Cycloviolacin O2Viola odorataGIPCGESCVWIPCISSAIGCSCKSKVCYRN
9AP01121Vibi EAlpine violet Viola bifloraGIPCAESCVWIPCTVTALIGCGCSNKVCYN
10AP01123Vibi GAlpine violet Viola bifloraGTFPCGESCVFIPCLTSAIGCSCKSKVCYKN
11AP01124Vibi HAlpine violet Viola bifloraGLLPCAESCVYIPCLTTVIGCSCKSKVCYKN
12AP01277Viscotoxin A3The European mistletoe, Viscum album L.KSCCPNTTGRNIYNACRLTGAPRPTCAKLSGCKIISGSTCPSDYPK
13AP01278Viscotoxin 1-PsThe European mistletoe, Viscum album L.KSCCPNTTGRNIYNTCRFGGGSREVCARISGCKIISASTCPSDYPK
14AP01279Viscotoxin A1Viscum album L. seedsKSCCPNTTGRNIYNTCRLTGSSRETCAKLSGCKIISASTCPSNYPK
15AP01280Viscotoxin CThe Asiatic Viscum album ssp. Coloratum ohwiKSCCPNTTGRNIYNTCRFAGGSRERCAKLSGCKIISASTCPSDYPK
16AP01281Viscotoxin A2Viscum album L.KSCCPNTTGRNIYNTCRFGGGSRQVCASLSGCKIISASTCPSDYPK
17AP01282Viscotoxin BViscum album L.KSCCPNTTGRNIYNTCRLGGGSRERCASLSGCKIISASTCPSDYPK
18AP01284Viscotoxin B2Viscum coloratum (Kom.) NakaiKSCCKNTTGRNIYNTCRFAGGSRERCAKLSGCKIISASTCPSDYPK
19AP01342Cn-AMP1Green coconut water, Cocos nuciferaSVAGRAQGM
20AP01343Cn-AMP2Green coconut water, Cocos nucifeTESYFVFSVGM
21AP01774Cliotide T1Clitoria ternateaGIPCGESCVFIPCITGAIGCSCKSKVCYRN
22AP01775Cliotide T2Clitoria ternateaGEFLKCGESCVQGECYTPGCSCDWPICKKN
23AP01776Cliotide T3Clitoria ternateaGLPTCGETCTLGTCYVPDCSCSWPICMKN
24AP01777Cliotide T4Clitoria ternateaGIPCGESCVFIPCITAAIGCSCKSKVCYRN
25AP01784Vaby AAfrica, the Ethiopian highlands, Viola abyssinicaGLPVCGETCAGGTCNTPGCSCSWPICTRN
26AP01785Vaby DAfrica, the Ethiopian highlands, Viola abyssinicaGLPVCGETCFGGTCNTPGCTCDPWPVCTRN
27AP01805Cr-ACP1Seeds, Cycas revolutaAWKLFDDGV
28AP01806Viba 15Viola philippicaGLPVCGETCVGGTCNTPGCACSWPVCTRN
29AP01807Viba17Viola philippicaGLPVCGETCVGGTCNTPGCGCSWPVCTRN
30AP01808Viphi AViola philippicaGSIPCGESCVFIPCISSVIGCACKSKVCYKN
31AP01809Viphi DViola philippicaGIPCGESCVFIPCISSVIGCSCSSKVCYRN
32AP01810Viphi EViola philippicaGSIPCGESCVFIPCISAVIGCSCSNKVCYKN
33AP01811Viphi FViola philippicaGSIPCGESCVFIPCISAIIGCSCSSKVCYKN
34AP01812Viphi GViola philippicaGSIPCEGSCVFIPCISAIIGCSCSNKVCYKN
35AP01813Mram 8Viola philippicaGIPCGESCVFIPCLTSAIDCSCKSKVCYRN
36AP01983Psyle APsychotria leptothyrsaGIACGESCVFLGCFIPGCSCKSKVCYFN
37AP01984Psyle EPsychotria leptothyrsaGVIPCGESCVFIPCISSVLGCSCKNKVCYRD
38AP01985Psyle CPsychotria leptothyrsaKLCGETCFKFKCYTPGCSCSYPFCK
39AP01986ChaC1Hybrid peptide of melittin and protamineGDACGETCFTGICFTAGCSCNPWPTCTRN
40AP01987ChaC2Chassalia chartaceaGIPCAESCVWIPPCTITALMGCSCKNNVCYNN
41AP01988ChaC4Chassalia chartaceaGASCGETCFTGICFTAGCSCNPWPTCTRN
42AP01989ChaC7Chassalia chartaceaIPCGESCVWIPCITAIAGCSCKNKVCYT
43AP01990ChaC8Chassalia chartaceaAIPCGESCVWIPCISTVIGCSCSNKVCYR
44AP01991ChaC10Chassalia chartaceaGEYCGESCYLIPCFTPGCYCVSRQCVNKN
45AP01992ChaC11Chassalia chartaceaIPCGESCVWIPCISGMFGCSCKDKVCYS
46AP02325Cliotide T7Clitoria ternateaGIPCGESCVFIPCTVTALLGCSCKDKVCYKN
47AP02326Cliotide T10Clitoria ternateaGVPCAESCVWIPCTVTALLGCSCKDKVCYLN
48AP02327Cliotide T12Clitoria ternateaGIPCGESCVYIPCTVTALLGCSCKDKVCYKN
49AP02328Cliotide T19Clitoria ternateaGSVIKCGESCLLGKCYTPGCTCSRPICKKD
50AP02329LunasinGlycine maxSKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD
51AP02332PaDefAvocado fruit, Persea americana var. drymifoliaCETPSKHFNGLCIRSSNCASVCHGEHFTDGRCQGVRRRCMCLKPC
52AP02340CyclosaplinSomatic seedlings, Santalum album L.RLGDGCTR
53AP02657Vigno 5Viola ignobilisGLPLCGETCVGGTCNTPGCSCGWPVCVRN
54AP02659DC1Hedyotis diffusaGAFLKCGESCVYLPCLTTVVGCSCQNSVCYRD
55AP02660DC2Hedyotis diffusaGAVPCGETCVYLPCITPDIGCSCQNKVCYRD
56AP02661DC3Hedyotis diffusaGTSCGETCVLLPCLSSVLGCTCQNKRCYKD
57AP05050Hyen DHybanthus enneaspermusGFPCGESCVYIPCFTAAIGCSCKSKVCYKN
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Jakubczyk, A.; Rybczyńska-Tkaczyk, K.; Grenda, A. Plant Antimicrobial Oligopeptides with Anticancer Properties as a Source of Biologically Active Peptides—An In Silico Study. Int. J. Mol. Sci. 2025, 26, 9189. https://doi.org/10.3390/ijms26189189

AMA Style

Jakubczyk A, Rybczyńska-Tkaczyk K, Grenda A. Plant Antimicrobial Oligopeptides with Anticancer Properties as a Source of Biologically Active Peptides—An In Silico Study. International Journal of Molecular Sciences. 2025; 26(18):9189. https://doi.org/10.3390/ijms26189189

Chicago/Turabian Style

Jakubczyk, Anna, Kamila Rybczyńska-Tkaczyk, and Anna Grenda. 2025. "Plant Antimicrobial Oligopeptides with Anticancer Properties as a Source of Biologically Active Peptides—An In Silico Study" International Journal of Molecular Sciences 26, no. 18: 9189. https://doi.org/10.3390/ijms26189189

APA Style

Jakubczyk, A., Rybczyńska-Tkaczyk, K., & Grenda, A. (2025). Plant Antimicrobial Oligopeptides with Anticancer Properties as a Source of Biologically Active Peptides—An In Silico Study. International Journal of Molecular Sciences, 26(18), 9189. https://doi.org/10.3390/ijms26189189

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop